



OPEN ACCESS

Short report

# Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial

Robert Bowser ,<sup>1,2</sup> Jiyang An,<sup>1,2</sup> Lahar Mehta,<sup>3</sup> Junliang Chen,<sup>3</sup> Jamie Timmons,<sup>3</sup> Merit Cudkowicz,<sup>4</sup> Sabrina Paganoni <sup>4,5</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2023-332106>).

<sup>1</sup>Departments of Neurology and Translational Neuroscience, Barrow Neurological Institute, Phoenix, Arizona, USA

<sup>2</sup>nVector, Inc, Phoenix, Arizona, USA

<sup>3</sup>Amylyx Pharmaceuticals, Inc, Cambridge, Massachusetts, USA

<sup>4</sup>Sean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

<sup>5</sup>Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts, USA

## Correspondence to

Dr Robert Bowser, Departments of Neurology and Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ 85013, USA; Robert.Bowser@dignityhealth.org

Received 28 June 2023

Accepted 25 October 2023

Published Online First 2 December 2023



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Bowser R, An J, Mehta L, et al. *J Neurol Neurosurg Psychiatry* 2024;**95**:605–608.

## ABSTRACT

**Background** An oral sodium phenylbutyrate and taurursodiol combination (PB and TURSO) significantly reduced functional decline in people living with amyotrophic lateral sclerosis (ALS) in the CENTAUR trial. Biomarkers linking clinical therapeutic effect with biological changes are of high interest in ALS. We performed analyses of neuroinflammatory biomarkers associated with ALS in the literature, including YKL-40 (also known as chitinase-3-like protein 1), chitinase 1 (CHIT1) and C reactive protein (CRP), in plasma samples collected in CENTAUR.

**Methods** Log<sub>10</sub>-transformed plasma biomarker measurements were analysed using a linear mixed-effects model. Correlation between paired biomarker concentrations and ALS Functional Rating Scale-Revised (ALSFRS-R) total scores was assessed via Pearson correlation coefficients.

**Results** By week 24, geometric least squares mean YKL-40 plasma concentration decreased by approximately 20% ( $p=0.008$ ) and CRP by 30% ( $p=0.048$ ) in the PB and TURSO versus placebo group. YKL-40 ( $r$  of  $-0.21$ ;  $p<0.0001$ ) and CRP ( $r$  of  $-0.19$ ;  $p=0.0002$ ) concentration correlated with ALSFRS-R total score. CHIT1 levels were not significantly different between groups.

**Conclusions** YKL-40 and CRP plasma levels were significantly reduced in participants with ALS receiving PB and TURSO in CENTAUR and correlated with disease progression. These findings suggest YKL-40 and CRP could be treatment-sensitive biomarkers in ALS, pending further confirmatory studies.

**Trial registration number** <https://clinicaltrials.gov/study/NCT03127514>

## INTRODUCTION

Safety and efficacy of an oral, fixed-dose sodium phenylbutyrate and taurursodiol combination (PB and TURSO) in amyotrophic lateral sclerosis (ALS) were evaluated in the multicentre phase 2 CENTAUR trial encompassing randomised placebo-controlled and open-label extension phases.<sup>1–3</sup> The randomised phase primary end point was met, with PB and TURSO significantly slowing functional decline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) over 24 weeks compared

with placebo.<sup>2</sup> Changes in plasma phosphorylated neurofilament heavy chain and neurofilament light chain (NfL) concentrations were evaluated as a secondary outcome and showed no between-group differences.<sup>2–4</sup> Plasma samples were prospectively collected from CENTAUR participants for potential future biomarker analyses.<sup>4</sup>

Neuroinflammatory biomarkers may add value beyond other biomarkers for assessing disease progression and therapeutic response in ALS. Chitinases, a class of hydrolases expressed by activated microglia and astrocytes, have emerged as potential prognostic biomarkers in ALS given prominence of glial activation in the neuroinflammatory response.<sup>5</sup> ALS is also characterised by a peripheral immune response that includes chitinase expression by activated myeloid cells, largely in response to cytokines.<sup>5–6</sup> PB and TURSO was previously shown to significantly reduce concentration of the chitinase YKL-40 (also known as chitinase-3-like protein 1) in cerebrospinal fluid (CSF) compared with placebo in adults with mild cognitive impairment and mild to moderate Alzheimer's disease (AD) dementia in a 24-week phase 2, multicentre, randomised trial (PEGASUS).<sup>7</sup> While most YKL-40 data in ALS are also in CSF, limited data in blood (mainly serum)<sup>5–8</sup> prompted our interest in evaluating plasma YKL-40 in an interventional trial setting.

Here, we describe results of exploratory post hoc analyses of neuroinflammatory biomarkers, including YKL-40, chitinase 1 (CHIT1) and the systemic inflammatory biomarker C reactive protein (CRP), in plasma samples from participants with ALS from CENTAUR. Results of these analyses were presented at the 2022 Annual Northeast Amyotrophic Lateral Sclerosis Consortium Meeting.<sup>4</sup>

## METHODS

Detailed methods for the CENTAUR randomised phase (NCT03127514) are reported elsewhere.<sup>1–2</sup> CENTAUR enrolled adults with definite ALS (revised El Escorial criteria<sup>9</sup>)  $\leq 18$  months from symptom onset and slow vital capacity  $>60\%$  predicted. Participants were randomised 2:1 to receive PB and TURSO (3g PB/1g TURSO) or matching placebo by mouth or feeding tube for 24

**Table 1** Plasma biomarker concentrations\*

Biomarker	Baseline†		Week 12‡		Week 24‡		P value§
	PB and TURSO (n=81)	Placebo (n=45)	PB and TURSO (n=81)	Placebo (n=45)	PB and TURSO (n=81)	Placebo (n=45)	
YKL-40	32.7 (1.98)	31.5 (1.69)	31.6 (1.05)	35.2 (1.06)	31.4 (1.06)	38.8 (1.08)	0.008
CHIT1	35.4 (3.85)¶	40.5 (2.23)	33.5 (1.12)	35.8 (1.12)	31.5 (1.13)	35.9 (1.14)	0.094
CRP	1686.7 (3.10)	2029.1 (4.58)	1817.9 (1.11)	2185.6 (1.12)	1833.6 (1.14)	2650.2 (1.18)	0.048

\*All concentrations expressed in ng/mL.  
†Geometric mean (SD) concentration.  
‡Geometric least-squares mean (SE) concentration (log<sub>10</sub>-transformed<sup>8</sup>) from a random-slope, shared-baseline, linear mixed-effects model adjusted for age and ALSFRS-R slope interacting with time.  
§For comparison between PB and TURSO group versus placebo group, calculated using shared-baseline, mixed-effects model.  
¶Excludes one participant who had a non-positive value for CHIT1 concentration at baseline, as non-positive values cannot be log-transformed.  
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; CHIT1, chitinase 1; CRP, C reactive protein; PB and TURSO, sodium phenylbutyrate and taurursodiol; YKL-40, chitinase-3-like protein 1.

weeks. Continuation of stable-dose riluzole and/or edaravone was permitted.

Blood samples were drawn at baseline and every 6 weeks thereafter through week 24 (or early discontinuation) to obtain plasma and stored in the NEALS biorepository.<sup>10</sup> YKL-40, CHIT1 and CRP immunoassays were conducted in a blinded manner using 0.5-mL plasma samples. YKL-40 and CHIT1 assays were developed by the Bowser Laboratory at the Barrow Neurological Institute, while the CRP assay was from Meso Scale Discovery (MSD). All assays were performed within the Clinical Laboratory Improvement Amendments–certified laboratory at *n*Vector (previously Iron Horse Diagnostics) on the MSD platform and demonstrated a <5% coefficient of variation (CV) for intra-assay and interassay quality controls and standards; the average CV across all samples was <4%.

As for all prespecified efficacy outcomes in CENTAUR, the participant population for these analyses was the modified intention-to-treat (mITT) population (ie, all participants who received ≥1 dose of study medication and had ≥1 postbaseline ALSFRS-R assessment). Specifically, participants with ≥1 post-baseline plasma sample collected over the 24-week randomised phase were included. First, log<sub>10</sub>-transformed plasma biomarker measurements<sup>8</sup> were analysed using a random-slope, shared-baseline, linear mixed-effects model adjusted for age and ALSFRS-R slope (ie, rate of ALSFRS-R total score change from symptom onset) interacting with time. Geometric least squares (LS) mean biomarker concentrations were calculated for each treatment group; given paucity of data at other time points (weeks 6 and 18), results for only weeks 12 and 24 are presented. Second, change-from-baseline analyses that did not assume a shared baseline were performed for all biomarkers. Geometric mean ratios from a mixed model for repeated measures without linear trend assumption were also calculated for weeks 12 and 24. Finally, Pearson correlation coefficients were calculated to assess the correlation between plasma concentrations of YKL-40, CHIT1 and CRP paired with ALSFRS-R total score and between concentrations of each biomarker paired with ALSFRS-R slope.

## RESULTS

Of 135 participants in the mITT population (PB and TURSO, n=87; placebo, n=48), 126 (PB and TURSO, n=81; placebo, n=45) had plasma samples available for these analyses. Summary baseline biomarker concentrations are shown in [table 1](#). Additional baseline characteristics for this population are summarised in online supplemental table 1 and were generally similar to those in the overall mITT population.<sup>2</sup>


Geometric LS mean YKL-40 plasma concentration was 10% lower (ratio, 0.90; 95% CI 0.83 to 0.97) at week 12 and approximately 20% lower (ratio 0.81; 95% CI 0.69 to 0.94) at week 24 in the PB and TURSO versus placebo group (p=0.008; [table 1](#)). Furthermore, YKL-40 concentration correlated with ALSFRS-R total score (r of -0.21; p<0.0001) and ALSFRS-R slope (r of 0.11; p=0.034). Change-from-baseline analyses also showed significant reduction in plasma YKL-40 concentration in the PB and TURSO versus placebo group (p=0.002; [figure 1](#)).

Geometric LS mean CHIT1 plasma levels were not significantly different between treatment groups ([table 1](#)). CHIT1 concentration did not correlate with ALSFRS-R total score (r of -0.05; p=0.326) or slope (r of 0.10; p=0.061). Change-from-baseline analyses showed no significant differences between groups (p=0.247; online supplemental figure 1). Geometric LS mean CRP concentration was 17% lower (ratio 0.83; 95% CI 0.69 to 1.00) at week 12 and approximately 30% lower (ratio 0.69; 95% CI 0.48 to 1.00) at week 24 in the PB and TURSO versus placebo group (p=0.048; [table 1](#)). CRP concentration correlated with ALSFRS-R total score (r of -0.19; p=0.0002) and slope (r of 0.21; p<0.0001). Change-from-baseline analyses showed significant reduction in plasma CRP concentration in the PB and TURSO versus placebo group (p=0.018; online supplemental figure 2).

## DISCUSSION

In our analyses of neuroinflammatory biomarkers in participants with ALS from CENTAUR, PB and TURSO significantly reduced plasma concentrations of YKL-40 and CRP but not CHIT1 relative to placebo over the 24-week randomised phase, with reductions observed as early as week 12. YKL-40 and CRP concentration further correlated significantly with disease progression as measured by the ALSFRS-R, the most widely used functional end point in ALS trials<sup>11</sup> and the primary efficacy outcome in CENTAUR.

CSF YKL-40 concentration has been shown to be elevated in ALS and correlates with clinical measures of disease severity, including the ALSFRS-R, progression rate and survival.<sup>5 12</sup> However, blood-based biomarkers offer the advantages of being more cost- and time-efficient and less invasive than CSF-based biomarkers.<sup>13</sup> While few studies have explored longitudinal blood levels of YKL-40 in ALS,<sup>8</sup> blood YKL-40 levels have been shown to be a treatment-responsive biomarker for multiple sclerosis.<sup>14</sup> Notably, in line with the current analysis, PB and TURSO significantly reduced CSF YKL-40 levels compared with placebo



**Figure 1** Change in YKL-40 plasma concentration relative to baseline over 24 weeks. Log<sub>10</sub>-transformed YKL-40 concentration measurements<sup>8</sup> were analysed using a random-slope, shared-baseline, linear mixed-effects model adjusted for age and ALSFRS-R slope interacting with time (coloured lines, with shading reflecting SEs). Geometric mean ratios (solid dots) and 95% CIs from an MMRM model without linear trend assumption are shown at weeks 12 and 24. ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; MMRM, mixed model for repeated measures; PB and TURSO, sodium phenylbutyrate and taurursodiol; YKL-40, chitinase-3-like protein 1.

in the PEGASUS trial in AD, a condition in which plasma and CSF YKL-40 levels have been shown to modestly correlate.<sup>15</sup>

CRP is a sensitive marker of systemic inflammation that is widely used given its availability and reliability. A systematic review found that CRP was significantly elevated and correlated with disease progression and survival in the majority of studies evaluating this biomarker in ALS, primarily in blood.<sup>6</sup> CRP level was also noted to significantly decrease after riluzole administration in an unblinded surveillance study of people with ALS presenting to a single clinic setting, suggesting CRP may be a potential biomarker for assessing treatment responsiveness in this population.<sup>16</sup> However, CRP may have limitations as a neuroinflammatory biomarker in ALS, including potential for confounding by comorbid inflammatory conditions<sup>6</sup> and the high variability observed for this biomarker.<sup>17</sup> Like YKL-40, CHIT1 has been shown to be elevated in ALS<sup>5,12</sup> but is primarily expressed by circulating cells of myeloid lineage.<sup>5,18</sup> In this analysis, CHIT1 levels did not differ significantly between treatment groups.

In contrast to YKL-40 and CRP in the current analyses, plasma neurofilament levels were not significantly changed with PB and TURSO treatment in CENTAUR.<sup>2</sup> PB and TURSO similarly had no significant effect on CSF NfL levels over a similar duration in the PEGASUS trial in AD.<sup>7</sup> While neurofilaments are a promising biomarker for ALS, the mechanistic linkage to ALS remains under study and other biomarkers may capture different aspects of ALS pathophysiology; though some studies have shown concomitant effects on clinical outcomes and neurofilament levels, others showed clinical effects without changes in neurofilament levels.<sup>2,19,20</sup> Ultimately, translation of the differential effects of PB and TURSO on plasma biomarkers in CENTAUR into the exact mechanism of PB and TURSO in ALS requires further study.

## CONCLUSIONS

We demonstrated significantly reduced YKL-40 and CRP plasma levels in participants receiving PB and TURSO in CENTAUR,

with lower YKL-40 and CRP concentrations correlating with higher ALSFRS-R total scores and lower rate of ALSFRS-R total score decline through 24 weeks. Analyses of neuroinflammatory biomarkers in the ongoing 48-week phase 3 clinical trial of PB and TURSO in ALS (PHOENIX) are planned to confirm these results. Ultimately, further delineation of the utility of these biomarkers in ALS may provide a tool for evaluating therapies targeting neuroinflammation in ALS trials.

**X** Robert Bowser @BiomarkerBob, Merit Cudkowicz @MeritCudkowicz and Sabrina Paganoni @PaganoniMDPhD

**Acknowledgements** The authors would like to thank the people living with ALS who participated in the CENTAUR trial, as well as their families and caregivers, and the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS). Lara Primak, MD, and Nikhilesh Sanyal, PhD, of PRECISIONscientia provided medical writing assistance with the development and revision of the manuscript under the direction of the authors, with financial support from Amylyx Pharmaceuticals, Inc., and in compliance with international Good Publication Practice guidelines.

**Contributors** MC and SP contributed to conceptualisation and design of the CENTAUR trial. RB, JA, MC and SP participated in acquisition of data. RB, JA and JC performed all statistical analyses. RB and JA provided assay development. JT and LM contributed to drafting of the manuscript. All authors take responsibility for the integrity of the data and the accuracy of the data analysis and critically reviewed interim and final versions of the manuscript.

**Funding** The CENTAUR trial was funded by Amylyx Pharmaceuticals, Inc., ALS Finding a Cure, and The ALS Association. The trial sponsor, Amylyx Pharmaceuticals, Inc., collaborated with the Northeast ALS Consortium network ([www.neals.org](http://www.neals.org)) in the design and execution of the trial. Amylyx provided active drug and placebo; participated in data analysis and manuscript development; and provided funding for writing support in the development of the manuscript. All other funders had no role in any aspect of the trial or in manuscript development.

**Competing interests** RB reports receiving laboratory supplies from *nVector* for the biomarker assays used in these analyses; consulting fees from MT Pharma, RRD International, BrainStorm and Cell Therapeutics unrelated to this manuscript; consulting fees from Amylyx Pharmaceuticals, Inc., related to this manuscript; a pending patent with *nVector*; and stock options in *nVector*, AcuraStem and Aural Analytics. JA reports stock options in *nVector*. LM, JC and JT are full-time employees of and have stock option ownership in Amylyx. MC reports consulting fees from Lilly, Immunity Pharm Ltd, Orion, Cytokinetics, Wave Life Sciences, Takeda, Avexis, Biogen, Helixsmith, Sunovion Pharmaceuticals Inc., Disarm, ALSpharma, RRD International, Transposon, QurAlis, Regeneron Pharmaceuticals, AB Science, Locust

Walk, NeuroSense Therapeutics, Faze Medicines, Arrowhead Pharmaceuticals, VectorY Therapeutics, Servier, Eledon Pharmaceuticals, Pasithea Therapeutics and Denali Therapeutics and stock in Praxis. SP reports research grants from Amylyx related to this manuscript; research grants from the National Institutes of Health, Alector Therapeutics, Biohaven, Cytokinetics, Anelixis Pharmaceuticals, Revaliesio Corporation, UCB, Clene, Prilenia, Seelos Therapeutics, Calico and Denali Therapeutics unrelated to this manuscript; consulting fees from Frequency Therapeutics, SOLA Pharmaceuticals, Stealth BioTherapeutics, Orion, Roche, Janssen, Arrowhead and Amylyx; honoraria from Medscape; and board membership in the Association of Academic Physiatrists.

**Patient consent for publication** Not applicable.

**Ethics approval** The CENTAUR trial involved human participants and was approved by a central institutional review board, the Partners Human Research Committee, for all trial sites (no reference number or ID associated). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Deidentified participant data will be made available on reasonable request. Requests for data sharing can be sent to [info@amylyx.com](mailto:info@amylyx.com).

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Robert Bowser <http://orcid.org/0000-0001-5404-7259>

Sabrina Paganoni <http://orcid.org/0000-0003-0505-1168>

#### REFERENCES

- Paganoni S, Hendrix S, Dickson SP, *et al*. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. *J Neurol Neurosurg Psychiatry* 2022;93:871–5.
- Paganoni S, Macklin EA, Hendrix S, *et al*. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. *N Engl J Med* 2020;383:919–30.
- Paganoni S, Watkins C, Cawson M, *et al*. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. *Muscle Nerve* 2022;66:136–41.
- Bowser R, An J, Mehta L, *et al*. Improvement in a plasma biomarker of neuroinflammation, chitinase-3-like protein (CHI3L1/YKL-40), in the CENTAUR trial. *Muscle Nerve* 2022;66:S16–7.
- Gaur N, Perner C, Witte OW, *et al*. The chitinases as biomarkers for amyotrophic lateral sclerosis: signals from the CNS and beyond. *Front Neurol* 2020;11:377.
- Kharel S, Ojha R, Preethish-Kumar V, *et al*. C-reactive protein levels in patients with amyotrophic lateral sclerosis: a systematic review. *Brain Behav* 2022;12:e2532.
- Arnold SE, Knowlton N, Williams VJ, *et al*. Cerebrospinal fluid biomarker effects from a fixed-dose combination of sodium phenylbutyrate and taurursodiol in Alzheimer's disease: results from the PEGASUS trial. *J Prev Alzheimers Dis* 2022;9:S47–8.
- Vu L, An J, Kovalik T, *et al*. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. *J Neurol Neurosurg Psychiatry* 2020;91:350–8.
- Brooks BR, Miller RG, Swash M, *et al*. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000;1:293–9.
- Otto M, Bowser R, Turner M, *et al*. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. *Amyotroph Lateral Scler* 2012;13:1–10.
- van Eijk RPA, Kliet T, van den Berg LH. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. *Curr Opin Neurol* 2020;33:655–61.
- Dreger M, Steinbach R, Otto M, *et al*. Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2022;93:422–35.
- O'Bryant SE, Mielke MM, Rissman RA, *et al*. Blood-based biomarkers in alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. *Alzheimers Dement* 2017;13:45–58.
- Matute-Blanch C, Rio J, Villar LM, *et al*. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. *J Neuroimmunol* 2017;303:62–5.
- Craig-Schapiro R, Perrin RJ, Roe CM, *et al*. YKL-40: a novel prognostic fluid biomarker for preclinical alzheimer's disease. *Biol Psychiatry* 2010;68:903–12.
- Sanjak M, Bravver EK, Bockenek W, *et al*. C-reactive protein (CRP) is significantly higher in amyotrophic lateral sclerosis (ALS) patients on non-invasive ventilation (NIV) and tracheostomy-invasive ventilation (TIV) compared with ALS patients at intake clinic evaluation and decreases following riluzole administration – is CRP potentially a biomarker for treatment responsiveness. *Neurology* 2018;P4:447.
- van den Berg VJ, Umans VAWM, Brankovic M, *et al*. Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMArCS study. *Clin Chem Lab Med* 2020;58:2099–106.
- Masrori P, De Schaepdryver M, Floeter MK, *et al*. Prognostic relationship of neurofilaments, Chit1, YKL-40 and MCP-1 in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2022;93:681–2.
- Esselin F, De la Cruz E, Hirtz C, *et al*. Repeated neurofilament light chain measurements did not capture riluzole therapeutic effect in amyotrophic lateral sclerosis patients. *CNS Neurosci Ther* 2022;28:1532–8.
- Miller TM, Cudkovic ME, Genge A, *et al*. Trial of antisense oligonucleotide tofersen for SOD1 ALS. *N Engl J Med* 2022;387:1099–110.